We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs
News

Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs

Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs
News

Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs

Read time:
 

Want a FREE PDF version of This News Story?

Complete the form below and we will email you a PDF version of "Shuwen Biotech and Bliss Biopharmaceutical Partner on Companion Diagnostics for Cancer Drugs"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

Shuwen Biotech Co. Ltd., an emerging leader in innovative diagnostic products and services announced it has signed a partnership agreement with Bliss Biopharmaceutical Co., Ltd., a biopharmaceutical company engaged in the discovery, development and commercialization of biotherapeutics for unmet medical needs.

Under the agreement, Shuwen will develop companion diagnostics for Bliss’ oncology drug candidates. Shuwen also commits to provide testing services in its CAP-certified central labs for BlissBio’ clinical trials. The terms of the collaboration are undisclosed.

“Companion diagnostics and precision medicine are Shuwen’s major focus. We have partnered with a number of pharmaceutical companies. This collaboration will fuel continued innovation by BlissBio and further demonstrate how Shuwen can deliver value through its strong companion diagnostics development team and its CAP-accredited lab facilities,” said Jay Z. Zhang, Shuwen’s Chairman and Chief Executive Officer.

“We have some of the best-in-class biologics in development. Shuwen provides versatile technologies that may enable the precise selection of the most suitable patients for our drug candidates, thus increasing the competitiveness of our products. We are very happy to work with Shuwen,” commented Dr. Ziping Wei, BlissBio’ Chief Executive Officer.
Advertisement